|
| Portfolio |
| HIV and Human Retroviruses |
| Arisyn Therapeutics is developing a novel series of inhibitors which target human cells which are infected with HIV, reducing the level of virus produced from these cells and allowing existing HAART therapies or immune-boosting therapeutic strategies to better inhibit active virus replication in the body. The Arisyn portfolio of HIV compounds includes three inhibitors which inhibit HIV transcription and one compound which effectively inhibits both HIV and hepatitis C virus, allowing for a therapeutic option for co-infected patients. |
| ATI-0917 (formerly FB636) |
| Initially developed by The Procter & Gamble Company, ATI-0917 is a novel inhibitor of HIV replication and would represent the first of an entirely new and much sought after class of inhibitors which inhibit replication of virus from cells which are already infected with virus. ATI-0917 inhibits the production of viral messenger RNA in. M o r e . . . . . |
| ATI-0409 (formerly PG-301995) |
| Like ATI-0917, ATI-0409 was developed by The Procter & Gamble Company and has significant activity against HIV production from chronically or latently infected cells. However, whereas ATI-0917 appears to inhibit the production of RNA required for the production of HIV structural proteins and progeny viral genomic RNA, ATI-0409 inhibits all HIV RNA synthesis. M o r e . . . . . |
| ATI-0312 (formerly FB642) |
| ATI-0312 was also developed by The Proctor & Gamble Company and is distinct from ATI-0917 and ATI-0409 in that it is the most highly effective of the Arisyn inhibitors in preventing the acute infection of human target cells as well as causing significant reduction in the amount of virus produced from chronically infected cells. M o r e . . . . . |
| |
| Hepatitis and Hepatitis-HIV Co-Infections |
| ATI-0810 (formerly PG301029) |
| ATI-0810 has been found to inhibit the replication of hepatitis C virus by interfering with late stage replication events involved with RNA and protein production. Mechanistic evaluations suggest that the compound inhibits HCV replication by a unique mechanism which does not involve inhibition of virus entry, M o r e . . . . . |
| Influenza and Human Respiratory Viruses |
| Arisyn Therapeutics has tested over 150 compounds with molecular features similar to our lead therapeutic candidates for activity against human influenza virus and human rhinovirus and has identified five lead compounds for potential development. Upon selection of the clinical candidate for development, Arisyn will explore novel methods for delivery of this molecule including traditional oral dosing as well as nasal aerosol dosing. |
| Herpes Viruses |
| Arisyn has identified a lead molecule with in vitro activity against both the human Kaposi’s Sarcoma etiologic agent (HHV-8) and herpes simplex virus Type 2 (HSV-2). The lead compound (ATI-0607) is currently being evaluated for range and mechanism of action, potential for resistant virus generation and activity in combination with other approved herpes virus drugs. |
| Cancer |
| ATI-0312 (Carbendazim) |
| Phase 1 human clinical trials have been performed with ATI-0312 and the safety of the compound has been confirmed in these studies. Although the compounds have shown efficacy with regard to stabilizing tumor growth in the Phase 1 study patients, additional formulation development is M o r e . . . . . |
| |
Member of the Frederick Innovative Technology Center